Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. - Wikidata - awgldk - TriplyDB

Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.

Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q36929831

about

Novel agents for chronic lymphocytic leukemia The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date Lenalidomide and chronic lymphocytic leukemia Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups Advances in treating chronic lymphocytic leukemia Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a review Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma.Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?Expanding role of lenalidomide in hematologic malignancies Ibrutinib: a paradigm shift in management of CLL.Target Therapy in Hematological Malignances: New Monoclonal Antibodies.Combination immune therapies to enhance anti-tumor responses by NK cells.Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia.Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.Treatment of elderly patients with chronic lymphocytic leukemia: an unmet cinical need.Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors.Emerging drugs for T-cell lymphoma.Emerging therapies for refractory chronic lymphocytic leukemia.A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.The genomic landscape of chronic lymphocytic leukaemia: biological and clinical implications.Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia?Shifting paradigms in the treatment of chronic lymphocytic leukemia.Promising therapies for the treatment of chronic lymphocytic leukemia.An update on current and prospective immunotherapies for chronic lymphocytic leukemia.Integrating oncogeriatric tools into the management of chronic lymphocytic leukemia: current state of the art and challenges for the future.What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.Chronic lymphocytic leukemia (CLL)-Then and now.

P2860

Q21198858-7E315ADA-DC28-4552-AC5F-D4BF56FA697C Q26751006-321A3202-1DD7-4762-A6A5-7D765DAC5F65 Q26752518-B99F2BC4-1838-423B-92DB-84692841AED9 Q26798062-217D73DE-D637-486B-ACF8-86459C4411C2 Q26823597-4D323C81-27ED-4F23-BA3A-21DF9C5B6A2F Q28082086-A3F26301-776F-4762-A00D-F2E1E399FA32 Q33417117-5742F59C-F0C8-4685-ACE2-79D4E47705A0 Q33429161-FD0D8331-6329-41E7-AB93-C37B84C64877 Q33436535-73616E54-7A91-46CB-A776-20BD21E592E8 Q33796183-C5633394-94FD-4C22-828A-A8D1870EED10 Q33913537-06253A5B-FEE3-4ABD-8AC5-B8232D48E747 Q34019917-9FED4562-7DF1-424E-B773-B1DFED694584 Q34052075-57F61853-BF83-4915-BD03-9EE2A96CB296 Q34348572-B0EFF04F-6D42-4A9B-A3AD-4B8AA00FA3F0 Q34365673-A6522EA5-C1FA-4044-A5D7-F08F55CD0A82 Q34625543-DF48146F-412C-4B79-A53E-BC4765F732EC Q34769213-98EEC958-F9B1-46A2-9D3D-6BF42DCA5C7F Q35592305-11780FF3-3463-4300-BD87-F4E11F35279A Q36739295-51CAFF9A-C5CB-4021-959D-FA52C7E4D54D Q36979140-FA640066-3F9A-4240-984E-22D6F1DA66AB Q37408550-772B76DC-5E11-4AB1-81E0-41F89AF58542 Q37427107-B94A45AA-BB64-473C-AE33-9E852FF84613 Q37429218-70D5FFA6-D5AA-4BEB-8D96-78C3AF85E8DC Q37610087-720F7743-AE58-4FC1-99A2-25B9C704F941 Q38110472-A4B0638D-3764-431F-8510-B74CF21B1642 Q38132818-E6F03C6A-4465-44FC-A2EB-02DEF7BB300A Q38155343-F358A067-245F-4927-8D81-E7B7E1BF0BAD Q38196943-76FECB77-ABE6-47E4-989B-EBC64E3D7693 Q38207143-14B741F4-A83B-4F6C-9116-38BFE6BAEC19 Q38231432-5493B19D-0648-444F-A9A2-05D03BC474C4 Q38286344-DA0A0483-62B8-498B-B2DB-FFB7E5773F6D Q38344296-0E595441-0CC9-42C3-9B68-B48C9A6FF1EA Q38357127-DD23FC1F-C241-4427-B9D6-5819B28BCEBC Q38366441-A1F7D4BC-E49F-4D4F-A27F-6A79A43F4063 Q38445357-ED70E2E9-4EC4-412B-9B02-51ED02BDF87E Q38489690-FFE87DA4-6B30-4F90-961A-DE2E69324A8F Q38586543-3524F1D7-5E7C-40C0-8D11-CD7015530273 Q38594364-F5913299-55C1-4282-8D26-9DB43B41C176 Q38646074-DA046D79-54C6-4975-BDE2-F1713BC6F825 Q38675358-105F8F3E-73E7-4874-875A-EA23CD83E16B

P2860

Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q36929831

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Phase II study of lenalidomide ...... chronic lymphocytic leukemia.

@en

type

label

Phase II study of lenalidomide ...... chronic lymphocytic leukemia.

@en

prefLabel

Phase II study of lenalidomide ...... chronic lymphocytic leukemia.

@en

P1433

Q36929831-936887C0-3721-4E73-9168-FC012348C808

P1476

Q36929831-007B324F-B107-4842-88D7-C7FA5C1A1EFB

P2093

Q36929831-20B119AE-DA4A-4E08-B89E-DE05B96A2EEF

Q36929831-821E0520-743C-4BAC-A88E-B9D826C50FDD

Q36929831-9CE28945-1E12-4256-8858-E859C58698E3

Q36929831-ABE2C3F5-8983-439A-A811-EEE69D402ED2

Q36929831-DA35B508-8B12-4E5C-88EF-B47D05640972

P2860

Q36929831-00523226-B56D-4D06-8C03-5B649109A508

Q36929831-01049684-9FF2-4E90-AE12-2830D42B3EBD

Q36929831-01DF5E00-1494-4CBC-AFB8-513B4D9BC4D4

Q36929831-058B612B-5995-4F6E-B32E-AF94723D7C71

Q36929831-091DF043-457A-4CE1-959B-F588C60F0E01

Q36929831-17810321-68CC-4920-804F-04977012CF57

Q36929831-1D48E0F4-5D29-4432-BB3F-AF81F2358E70

Q36929831-1E34026A-C2ED-4DF9-B70B-37EDA02ADDA4

Q36929831-22AE7790-6805-4AEA-9F6A-D5C70EDD993D

Q36929831-23734C18-8371-4709-B2EA-6A200D2997C1

P304

Q36929831-FE9A5299-F5CD-4CAE-BE8B-590727DAD2F9

P31

Q36929831-3C952602-D979-40A0-B0EF-C61B88538B5B

P356

Q36929831-A9DBD8BB-E2F4-4A37-BAA7-8252711B8027

P407

Q36929831-40E2A46B-4AE6-40B5-A5DB-4FCD0C71B388

P433

Q36929831-926CA370-D1A0-4BF4-8678-7E84F85BD714

P478

Q36929831-2E1D3CE3-CF1D-4758-BF4A-B006B82F2559

P50

Q36929831-019B42DF-AA0D-4CA4-9943-FFF3FF04CA9D

Q36929831-0DE48782-11B1-4961-B34C-610B320119B7

Q36929831-33D4EF05-AA4A-413E-A81B-84174537D6D0

Q36929831-E26559DC-2E46-4006-8D93-436B962F3BFA

P577

Q36929831-68764AC9-6ABD-4B12-B68A-2F2F496B0137

P5875

Q36929831-AD400E29-6F0E-4F12-B56C-B68AC49A7075

P698

Q36929831-8D719CED-98CF-487B-AFC2-CE52EBA17BD9

P921

Q36929831-59E1B471-FB8A-494F-89CD-8DC4954860D7

Q36929831-EE0231EA-647E-48E5-8D91-130D141A9855

P932

Q36929831-45FD2C77-F1AF-4688-B03F-892ADA7BDFDA

P356

JCO.2012.42.8623

P1433

Journal of Clinical Oncology

P1476

Phase II study of lenalidomide ...... chronic lymphocytic leukemia.

@en

P2093

Jan A Burger

http://www.w3.org/2001/XMLSchema#string

Rachel Sargent

http://www.w3.org/2001/XMLSchema#string

Sijin Wen

http://www.w3.org/2001/XMLSchema#string

Susan M O'Brien

http://www.w3.org/2001/XMLSchema#string

Xavier C Badoux

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Remission induction using alemtuzumab can permit chemotherapy-refractory chronic lymphocytic leukemia (CLL) patients to undergo allogeneic stem cell transplantation.

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

P304

584-591

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2012.42.8623

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Alessandra Ferrajoli

William G Wierda

Michael J. Keating

P577

2012-12-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233995735

http://www.w3.org/2001/XMLSchema#string

P698

23270003

http://www.w3.org/2001/XMLSchema#string

P921

P932

4878047

http://www.w3.org/2001/XMLSchema#string